Clinical Trials
52 trialsPilot Prospective Study for PET-CT Imaging in Participants With Relapsed/Refractory Acute Leukemias
National Institutes of Health Clinical Center (CC)
Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
Children's Oncology Group
Dynamic Individualized Risk Profiling of Patients With Relapsed/Refractory Lymphoid Malignancies and CD19-CAR T Cell Therapy (INTeRCePT 2.0)
University of Zurich
EPKEY_HSR
IRCCS San Raffaele
FIL_MOGA
Fondazione Italiana Linfomi - ETS
HL-R2-B2
University Hospital, Bordeaux
Drug-Eluting Bead-Based Transarterial Chemoembolization (DEB-TACE) as a Local Salvage Therapy for Large Lesions in Relapsed and Refractory Diffuse Large B-Cell Lymphoma
Fujian Medical University
Calquence CLL rr Japan PMS_Japan Post-Marketing Surveillance (PMS) Study - All Patient Investigation
AstraZeneca
A Study to Evaluate the Therapeutic Benefit of Tisagenlecleucel Compared to Existing Standard of Care in German Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma
Novartis
CAR-Multicenter Analysis (CAR-MA): Retrospective Study to Characterize CAR T-cell Outcomes and Related Toxicities in Children and Young Adults With B-ALL
National Institutes of Health Clinical Center (CC)
DECIDE
Max-Planck-Institute of Psychiatry
WGc-043
Ruijin Hospital
RevlimidPMS
Celgene
A Study to Evaluate the Relationship of Lenalidomide With Tumor Flare Reaction and High Tumor Burden in Participants With Relapsed or Refractory Mantle Cell Lymphoma
Celgene
A Study of Patients Who Received Inotuzumab Ozogamicin for B-cell ALL (Acute Lymphoblastic Leukemia) That Occurred Again After the Last Treatment
Pfizer
Immunotherapy in Lymphoma
Seoul St. Mary's Hospital
Long-term Follow-up Study in Patients Previously Treated With a Mustang Bio CAR-T Cell Investigational Product.
Mustang Bio
Salvage Treatment With Glofitamab in R/R B-NHL: a GIMEMA-FIL Study
Gruppo Italiano Malattie EMatologiche dell'Adulto
ISTODAX® for Intravenous Infusion Drug Use Results Survey- Relapsed or Refractory Peripheral T-Cell Lymphoma
Celgene
VENCLL regPMOS
AbbVie
ORCHID
Regeneron Pharmaceuticals
Hypoxia-Specific Imaging to Predict Outcomes of Chimeric Antigen Receptor T-cell Therapy
University of California, San Francisco
BRAVO
Samsung Medical Center
Collecting and Storing Blood Samples From Patients With Cancer
Rutgers, The State University of New Jersey
Childhood Acute Lymphoblastic Leukaemia: Follow-Up
University of Aarhus
HGMHRAEI/ALL
Hospital General de Mexico
Brentuximab Vedotin (Recombinant) for IV Infusion - Special Drug Use Surveillance (All-case Surveillance) "Relapsed or Refractory CD30+ Hodgkin's Lymphoma or Anaplastic Large Cell Lymphoma"
Takeda
HOLYFU
Federico II University
Study on the Role of FDG-PET in Patients With FL at Time of Relapse/Progression
Fondazione Italiana Linfomi - ETS
Lenalidomide Observational Study in Patients With Mantle Lymphoma in Relapse/Refraction. Spanish Programme RRMCL Results.
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Patient-reported and Clinical Outcomes in Adults With Relapsed or Refractory Hodgkin's Lymphoma Receiving Brentuximab Vedotin
Multinational Center for Quality of Life Research, Russia
Cortical Excitability and Inhibition in MDD
Mayo Clinic
Evaluation of ProALL miRs in Blood Specimen for Prediction of ALL Relapse Risk
Curewize Health Ltd.
Genetic Susceptibility and Risk of Second Cancers in Patients Who Have Undergone Stem Cell Transplant for Cancer
Vanderbilt-Ingram Cancer Center
Relapsed Malignant Blood Cancer After Allogeneic Hematopoietic Stem Cell Transplantation
National Institutes of Health Clinical Center (CC)
Pralatrexate for Relapsed or Refractory Peripheral T-cell Lymphoma
Samsung Medical Center
Methemoglobinemia in Young Patients With Hematologic Cancer or Aplastic Anemia Treated With Dapsone
Vanderbilt University Medical Center
MCL-004
Celgene
Retrospective Analysis on Relapsed/Refractory Aggressive Non Hodgkin Lymphoma Treated With Z-BEAM Plus ASCT
A.O.U. Città della Salute e della Scienza
Ribomustin in the Second Line Therapy of Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma
Astellas Pharma Inc
MabThera (Rituximab) in Combination With CHOP (or CHOP-like) Chemotherapy in Patients With Aggressive B-Cell Lymphoma
Hoffmann-La Roche
Genetic Study in Patients Receiving Treatment for Hodgkin's Disease or Childhood Brain Tumor
Duke University
RIPAL
Hospices Civils de Lyon
Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer
Columbia University
Early Detection of Graft-Versus-Host Disease in Patients Undergoing a Donor Bone Marrow Transplant
Mayo Clinic
Development of Strategies to Increase Enrollment in Clinical Trials for Children With Cancer
Children's Oncology Group
Quality of Life in Children Treated for Cancer
Children's Oncology Group
Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant
Vanderbilt-Ingram Cancer Center
Treatment Resistance Related With Gene Expression Profile of Diffuse Large B-cell Lymphoma
Samsung Medical Center
Ovarian Damage in Young Premenopausal Women Undergoing Chemotherapy for Cancer
Case Comprehensive Cancer Center